Long- and Short-Term Cost-Effectiveness of Once-Weekly Semaglutide versus Dulaglutide for the Treatment of Type 2 Diabetes in China: A Hypothetical Modeling Exercise

被引：0

作者：

Ying Hu ^{[1
]}

Huimin Zou ^{[2
]}

Yang Shen ^{[3
]}

Qi Ni ^{[4
]}

Yijun Li ^{[1
]}

Hao Zhang ^{[1
]}

Xianwen Chen ^{[5
]}

Carolina Oi Lam Ung ^{[2
]}

Hao Hu ^{[2
]}

Yiming Mu ^{[6
]}

机构：

[1] PLA General Hospital,Department of Endocrinology, First Medical Center of Chinese

[2] University of Macau,State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences

[3] Peking University,School of Public Health

[4] Peking University,China Center for Health Development Studies

[5] Novo Nordisk (China) Pharmaceuticals Co.,Centre for Pharmaceutical Regulatory Sciences

[6] Ltd.,Department of Public Health and Medicinal Administration, Faculty of Health Sciences

[7] University of Macau,undefined

[8] University of Macau,undefined

来源：

Diabetes Therapy | 2025年 / 16卷 / 5期

关键词：

Type 2 diabetes; Semaglutide; Dulaglutide; Cost-effectiveness analysis; China;

D O I：

10.1007/s13300-025-01716-9

中图分类号：

学科分类号：

摘要：

引用

页码：915 / 929

页数：14

共 50 条

[21] Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
Malkin, Samuel J. P.
Russel-Szymczyk, Monika
Liidemann, Girtel
Volke, Vallo
Hunt, Barnaby
DIABETES THERAPY, 2019, 10 (01) : 159 - 176
[22] Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
Johansen, Pierre
Chubb, Barrie
Hunt, Barnaby
Malkin, Samuel J. P.
Sandberg, Anna
Capehorn, Matthew
ADVANCES IN THERAPY, 2020, 37 (05) : 2427 - 2441
[23] Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
Pierre Johansen
Barrie Chubb
Barnaby Hunt
Samuel J. P. Malkin
Anna Sandberg
Matthew Capehorn
Advances in Therapy, 2020, 37 : 2427 - 2441
[24] Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
Samuel J. P. Malkin
Monika Russel-Szymczyk
Girtel Liidemann
Vallo Volke
Barnaby Hunt
Diabetes Therapy, 2019, 10 : 159 - 176
[25] COST-EFFECTIVENESS ANALYSIS OF ONCE-WEEKLY SEMAGLUTIDE FOR THE TREATMENT OF PATIENTS WITH TYPE 2 DIABETES IN MEXICO
Valdez-Huerta, R.
Moreno, D.
Hernandez, Paladio J. A.
VALUE IN HEALTH, 2022, 25 (07) : S429 - S429
[26] Once-weekly semaglutide for patients with type 2 diabetes: a cost-effectiveness analysis in the Netherlands
Hunt, Barnaby
Malkin, Samuel J. P.
Moes, Robert G. J.
Huisman, Eline L.
Vandebrouck, Tom
Wolffenbuttel, Bruce H. R.
BMJ OPEN DIABETES RESEARCH & CARE, 2019, 7 (01)
[27] The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States
Wang, Bruce
Roth, Joshua A.
Nguyen, Hiep
Felber, Eugene
Furnback, Wes
Garrison, Louis P.
PLOS ONE, 2015, 10 (04):
[28] Once-weekly semaglutide provides better health outcomes compared to dulaglutide as dual therapy in the treatment of type 2 diabetes: a cost-effectiveness analysis
Tikkanen, C. K.
Johansen, P.
Hunt, B.
Malkin, S.
Pollock, R. F.
DIABETOLOGIA, 2018, 61 : S426 - S427
[29] Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11
Evans, Marc
Chubb, Barrie
Malkin, Samuel J. P.
Berry, Sasha
Lawson, Jack
Hunt, Barnaby
DIABETES OBESITY & METABOLISM, 2023, 25 (02): : 491 - 500
[30] Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting
Peter Gæde
Pierre Johansen
Christian Klyver Tikkanen
Richard Fulton Pollock
Barnaby Hunt
Samuel Joseph Paul Malkin
Diabetes Therapy, 2019, 10 : 1297 - 1317

← 1 2 3 4 5 →